An open label randomized controlled trial compares inclisira…

An open label randomized controlled trial compares inclisiran 284 mg as a single injection on day 0, 3 months, then every 6 months to alirocumab 150mg every 14 days among patients who have a history of ASCVD and statin intolerance. In the inclisiran arm 10% of patients were on ezetimibe and in the alirocumab arm 15% of patient were on ezetimibe. The rate of major adverse cardiac events among patients using inclisiran compared to alirocumab was 1.13 (95%CI 0.96-1.30). Alirocumab decreased LDL more than inclisiran (36mg/dL versus 24mg/dL, respectively, p-value 0.04). Which of the following statements are true regarding this study? (SELECT ALL THAT APPLY)

A 63 yo male comes into your pharmacy inquiring about vaccin…

A 63 yo male comes into your pharmacy inquiring about vaccines. The patient typically receives his influenza vaccine annually with his last dose 1 year ago and has received no other vaccines in the last 30 years but to his knowledge received normal childhood vaccinations. The patient has a past medical history of hypertension, hyperlipidemia, newly diagnosed HIV, and seasonal allergies. His current medications include Biktarvy one tablet QD, Lisinopril 5 mg QD, Lipitor 20 mg QD, and Zyrtec 10 mg PRN seasonal allergies. The patient has an egg, nut, and shellfish allergies. Which vaccines is he eligible for? (SELECT ALL THAT APPLY)